ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7

Article activity feed

1. Version published to 10.1038/s41467-021-26178-y

   Oct 7, 2021
2. 

   Version published to 10.1101/2021.03.11.435000v3 on bioRxiv

   Jun 30, 2021
3. 

   ScreenIT

   Mar 15, 2021

   SciScore for 10.1101/2021.03.11.435000: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	IACUC: Ethics Statement: All animal experiments were conducted in an AAALAC International-accredited facility and were approved by the Rocky Mountain Laboratories Institutional Care and Use Committee following the guidelines put forth in the Guide for the Care and Use of Laboratory Animals 8th edition, the Animal Welfare Act, United States Department of Agriculture and the United States Public Health Service Policy on the Humane Care and Use of Laboratory Animals.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	Four groups of 10, 4-6-week-old female Syrian hamsters (Envigo Indianapolis, IN) were vaccinated …

   SciScore for 10.1101/2021.03.11.435000: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	IACUC: Ethics Statement: All animal experiments were conducted in an AAALAC International-accredited facility and were approved by the Rocky Mountain Laboratories Institutional Care and Use Committee following the guidelines put forth in the Guide for the Care and Use of Laboratory Animals 8th edition, the Animal Welfare Act, United States Department of Agriculture and the United States Public Health Service Policy on the Humane Care and Use of Laboratory Animals.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	Four groups of 10, 4-6-week-old female Syrian hamsters (Envigo Indianapolis, IN) were vaccinated with 2.5 × 108 infectious units of ChAdOx1 nCoV-19 vaccine or ChAdOx1-GFP delivered intramuscularly in two 50 µL doses into the posterior thighs 30 days prior to challenge.
   Cell Line Authentication	Contamination: Mycoplasma testing is performed at regular intervals and no mycoplasma was detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Antibodies were detected using affinity-purified polyclonal antibody peroxidase-labeled goat-anti-monkey IgG (Seracare, 074-11-021) in casein followed by TMB 2-component peroxidase substrate (Seracare, 5120-0047).	IgG suggested: None
   Experimental Models: Cell Lines
   Sentences	Resources
   VeroE6 cells were maintained in DMEM supplemented with 10% fetal bovine serum, 1 mM L-glutamine, 50 U/ml penicillin and 50 μg/ml streptomycin.	VeroE6 suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)
   Expression was performed in Freestyle 293-F cells (Thermofisher), maintained in Freestyle 293 Expression Medium (Gibco) at 37°C and 8% CO2 shaking at 130 rpm	293-F suggested: None
   Software and Algorithms
   Sentences	Resources
   Remaining reads were mapped to the SARS-CoV-2 2019-nCoV/USA-WA1/2020 genome (MN985325.1) or hCoV-19/England/204820464/2020 (EPI_ISL_683466) or hCoV-19/SouthAfrica/KRISP-K005325/2020 (EPI_ISL_678615) using Bowtie2 version 2.2.928 with parameters --local --no-mixed -X 1500.	Bowtie2 suggested: (Bowtie 2, RRID:SCR_016368)
   PCR duplicates were removed using picard MarkDuplicates (Broad Institute) and variants were called using GATK HaplotypeCaller version 4.1.2.029 with parameter –ploidy 2.	GATK suggested: (GATK, RRID:SCR_001876)
   Data availability statement: Data have been deposited in Figshare	Figshare suggested: (FigShare, RRID:SCR_004328)

   ---

   Results from OddPub: Thank you for sharing your data.

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Read the original source
4. 

   Version published to 10.1101/2021.03.11.435000v2 on bioRxiv

   Mar 15, 2021
5. 

   Version published to 10.1101/2021.03.11.435000v1 on bioRxiv

   Mar 11, 2021